Beam Therapeutics BEAM Institutional Ownership

Updated Oct 11, 2026

Beam Therapeutics Inc. (NASDAQ:BEAM) had 277 institutional holders reporting a position on Form 13F for the quarter ended June 30, 2026.

• Total holdings of BEAM shares rose 0.97% from Q1 2026, and the holder count rose 30.05% from Q2 2025.
• Among the 277 holders of Beam Therapeutics, 154 added to their positions, 75 reduced their stakes and 48 left their positions unchanged.
• The aggregate institutional position in Beam Therapeutics was 109.39Mn shares at the end of Q2 2026, up 1.05Mn from the prior quarter and up 4.69Mn from a year earlier.
• As of June 30, 2026, the biggest holder of Beam Therapeutics was FMR LLC with 12.61Mn shares.
• The biggest increases in BEAM positions during Q2 2026 came from Morgan Stanley (+1.3Mn shares), Contrarius Group Holdings Ltd (+1.08Mn shares), T. Rowe Price Associates Inc (+702.01K shares), BlackRock, Inc. (+509.97K shares) and Jupiter Asset Management LTD (+421.66K shares).
• On the other side, among holders that kept a position in Beam Therapeutics, the largest reductions in Q2 2026 came from ARK Investment Management LLC (-1.9Mn shares), Qube Research & Technologies Ltd (-890.68K shares), Kynam Capital Management, LP (-841.39K shares), Sumitomo Mitsui Trust Group, Inc. (-370.54K shares) and Amova Asset Management Americas, Inc. (-370.54K shares).
• Business Quant data shows the 10 biggest positions in Beam Therapeutics as of Q2 2026 were held by FMR LLC (12.61Mn shares), Farallon Capital Management, L.L.C. (10.24Mn shares), ARK Investment Management LLC (10.23Mn shares), BlackRock, Inc. (9Mn shares), State Street Corp (5.83Mn shares), Vanguard Portfolio Management LLC (4.92Mn shares), Vanguard Capital Management LLC (4.6Mn shares), ARCH Venture Management, LLC (4.54Mn shares), Sumitomo Mitsui Trust Group, Inc. (3.46Mn shares) and Amova Asset Management Americas, Inc. (3.46Mn shares).